Thursday - Chemical & Engineering News - American Chemical ...

Informex 2014 .......................... 3
Partnerships Key to Success. .............. 3
Conference schedule. .................... 4
Show-at-a-Glance. ....................... 5
SOCMA Management Services. ............ 6
ChemStewards Program Serves Up Benefits. . 7
Showcases: Part 2 ..................... 4–5
Five Minutes With…
Denis Geffroy, VP,
Business Development, Almac. .......... 9
Steward Tipson, VP, DrM. ................ 11
Edward S. Price, President, PCI Synthesis. ... 17
At Deadline: Late Breaking News. ......... 20
Exhibitor News. ...................... 8–21
Exhibition Map, List of Exhibitors ...... 12–13
Exhibitor Photos. ....................... 22
Advertiser Index. ....................... 21
Knowing the
Territory is Crucial
for API Sourcing in
Emerging Markets
The hurdles of doing business in Asian countries
require understanding the eclectic cultures
and the serpentine regulations as well as
assessing the capabilities of individual companies. “API
Sourcing in Emerging Markets” presented perspectives
on market growth in India and China, according to
experts on Wednesday.
India has had roots in the pharmaceutical market
since the government started a company there in 1901.
Thomas Speace, president of Neuland Laboratories
described the benefits of doing business with India as
relatively low cost manufacturing, abundant scientific
talent, English being the lingua franca, strong informa-
See API Sourcing page 23
Early Start Adds
to Green Chemistry
Success, Efficiency
Commitment to green chemistry means assessing
the world’s “finite and diminishing resources,”
according to David C. Constable, director of
the American Chemical Society (ACS) Green Chemistry
Institute, who presented a session on “Differentiating
Yourself from the Competition in the Green Supply
Chain” on Wednesday. Chemists should think about
human and environmental impact, and companies have
to design green chemistry into processes and find ways
to assess its effectiveness, he said.
“For instance, phosphorus is critical to the food
supply,” he said. “There is only a 300-year supply, and
we have no way to recycle it.” Green chemistry has
focused on eliminating toxin usage and eliminating or
reducing waste.
See Green Chemistry page 23

INFORMEX Show Daily | Thursday February 21 2013 | Anaheim Convention Center Anaheim California 3
InformEx 2014—A High Value Event
Pearl is the traditional gift
Throughout the year,
for 30th anniversaries—
Informex’s key audiences will
and like this precious
be interviewed and surveyed
gemstone—this milestone
and their valuable insight will
anniversary of InformexUSA will
help shape the 30th Anniversary
be a high value event in 2014.
event as well as future editions.
Taking place Jan. 21-24,
The most popular ideas, top
2014 in Miami, FL at the Miami
interests and objectives will
Beach Convention Center, this
be incorporated into the 30th
desirable venue is a convenient
anniversary event. In addition,
destination for Informex’s growing
educational programming, new
international audience.
show features and networking
This year, 34 percent of the
and business-building opportunities
will reflect the valuable
Informex audience is international
and that number is expected
research and insight shared by
to grow higher as Informex
the Informex community.
continues to be the global
The 30th anniversary is
marketplace for the chemical
already shaping up to be a
industry.
memorable event, with more
As Anaheim is in full swing,
than 80 companies re-signing
planning has already begun
for 2014 booths so far, an
for next year’s event. Show
increase over last year’s rebookings.
management is meeting with key
stakeholders and industry participants, as well as committed to investing time and Attendees at this year’s InformexUSA are invited to stop by Informex Booth 1709
resources to insure that the event stays at the forefront of market demands and to learn more about the show in Miami and how they can share their insight and
continues to meet the needs of the industry.
provide feedback on their Informex experience.
Intelligence, Association Partnerships for Industry Success
Informex is committed to working closely with key industry associations and
market research firms to promote the event, as well as foster industry growth
and attendees’ professional development.
With its on-going partnership with SOCMA, InformEx meets with the association
and many of its members throughout the year to ensure Informex is building a
high value and relevant event for the chemical industry. Informex also attends and
supports SOCMA’s events and participates in member activities throughout the year.
Recently, InformEx & PIERS, The Standard in Trade Intelligence, partnered
to create a one-of-a-kind report available for free download that examined top
markets for U.S. chemical exports based on the volume of waterborne shipments.
The report, Market Opportunities for U.S. Chemical Exports: An Examination of
Growth Across Major Markets, examined top markets for U.S. chemical exports
classified under chapters 28 & 29 of the harmonized tariff schedule.
In each of these markets, the report provides a macro-assessment of selected
commodities that have shown significant growth between 2007 and 2011 and
are traded in relatively high volume. The report was designed to give chemical
manufacturers, distributors, end users, and those servicing the chemical supply
chain, a high-level of view of top markets based on aggregate data for U.S.
chemical exports.
At the show this year, Informex partnered with BIOCOM, the largest regional life
science association in the world, representing more than 550 member companies in
Southern California. The association focuses on initiatives that positively influence
the region’s life science community in the development and delivery of innovative
products that improve health and quality of life. Its members where invited to
attend Informex and benefit from the networking, sourcing, and educational
opportunities that are presented here.
Informex also works with the Chemical Educational Foundation to promote and
enhance science education among every generation.
RX-360 and Green Chemistry Institute of the American Chemical Society help to
develop content and foster industry collaboration and awareness.
In the coming year, Informex will be working with even more associations and
content providers to extend its reach and best serve the needs of the industry.
P u b l i s h e d b y A m e r i c a n C h e m i c a l S o c i e t y
Publisher Kenneth M. Carroll
Editor Sharon Donovan
Reporter Ilene Schneider
Art Director Connie Hameedi
Photographers Peter Cutts
Advertising Sales USA
Dean Baldwin, Robert LaPointe,
Thomas Scanlan
Europe Uwe Riemeyer,
Paul Barrett, Nadia Liefsoens
Asia Minghua Lu, Angel Zu,
Mai Hashikura, Shigamaro Yatsui,
Faredoon Kuka
Production Manager
Joseph Davis
ACS Publications
Advertising Sales Group
480 East Swedesford Road
Wayne, PA 19087
Phone 610.964.8061/Fax
610.964.8071
http://cen.acs.org/onsite.html

4 INFORMEX Show Daily | Thursday February 21 2013 | Anaheim Convention Center Anaheim California
Part 2: Showcases Highlight Company Strengths, Growth
Editor’s Note: This roundup of InformexUSA Showcases is a Part 2 followup to
Tuesday’s presentations aimed at briefing attendees on companies’ most recent
developments within the industry. More showcase coverage will appear in the
InformexUSA Show Daily wrap edition.
Catalent is into heavy metal
Michelle Cree, a senior scientist at Catalent
Pharma Solutions, discussed new regulatory
expectations and solutions related to toxic
metals in the harmaceutical supply chain.
She related that pharmaceutical testing
for elemental impurities in excipients,
API (active pharmaceutical ingredient)
and drug products is necessary to ensure
product quality and consumer safety. USP
General Chapter 231 has been used since
1905 to assess “heavy metal” content in
pharmaceutical products.
Michelle Cree,
The talk discussed the reasons for
senior scientist, Catalent
replacing General Chapter 231 and outlined
the new requirements for USP Elemental Impurities testing as described in General
Chapters 232 and 233. Cree described strategies for compliance with these new
requirements and provided development and validation examples from case studies
performed in Catalent’s laboratories.
Headquartered in Somerset, NJ, the company serves thousands of innovators,
large and small, in more than 100 markets, including 36 of the top 50 biotech
companies and 49 of the top 50 pharmaceutical companies. Catalent employs
9,000 people and its team of more than 1,000 scientists supports 40 percent of
recent new drug approvals.
Chiral Quest announces future direction
Chiral Quest announced its new CEO
James Wu and its merger with Jiang Xi
Long Life Biopharmaceuticals, a commercial
manufacturing plant near Nanchang, in
Jiangxi Province, China.
Chiral Quest is a U.S.-based company
founded in 2000 and Jiangxi Long Life
was founded in 2009. While Chiral Quest
Suzhou is focused on R&D and pilot plant
operations, Chiral Quest Long Life is focused
on commercial scale manufacture. The
combined company has more than 100,000
L of manufacturing capacity, with expertise
Ian Lennon, senior VP, Chiral Quest
in high pressure asymmetric hydrogenation
and cryogenic reactions. The company has successfully developed and scaled
up many processes for the commercial manufacture of both chiral and achiral
intermediates.
Cambrex makes potent statement
Cambrex’s showcase highlighted its custom development and manufacturing
capabilities, including analytical development, process validation, and finished
dosage form manufacture.
John Michnick, associate director of sales and business development, said the
company’s high potency development center provides containment and rigorous controls
to reliably and safely develop and manufacture a wide range of high- and ultra-high
potency APIs and intermediates, including
oncologics and controlled substances.
Globally, Cambrex offers a variety of
technology-driven products and services
that accelerate the development of small
molecule therapeutics from custom
development to commercial manufacturing,
including high potency APIs and drug
intermediates. The company manufactures
more than 120 generic and branded
APIs, as well as advanced pharmaceutical
intermediates. The company’s commitment
John Michnick,
to quality, safety and regulatory compliance
associate director, Cambrex
allows Cambrex to seamlessly support its
clients’ API needs from clinical trials through commercial launch.
Founded in 1981 as CasChem, the company was renamed Cambrex in 1987.
Cambrex entered the pharmaceutical market in 1994 with the acquisition of
Nobel Pharma Chemistry. Through multiple acquisitions during the late 1990s, the
company entered the bioscience and chiral enzymatic catalyst markets.
Senn discusses practical peptide considerations
Senn Chemicals highlighted the synthetic
challenges of peptide-based therapeutics
at its showcase. According to Richard
Pariza, peptide-based therapeutics, as well
as peptidiomimetic drugs, present unique
challenges to synthetic chemists. New
reagents and techniques, as well as the
expertise of experienced peptide chemists,
are essential to the research-scale as well as
the manufacturing of these important new
drugs. The session focused on the practical
considerations that can ensure efficiency
and success in biotech/pharma peptide
Richard Pariza, Senn Chemicals
manufacturing.
Senn Chemicals was founded in 1963 and has been specializing in customized,
cost-effective solutions to a variety of compound, process and manufacturing
challenges. Senn’s cGMP manufacturing facilities, based outside of Zurich,
Switzerland, support its primary development, production and analytical capabilities.
The company currently has offices in Menlo Park and San Diego, California.
Senn Chemicals has been providing custom manufacturing services to
pharmaceutical, biotechnology, diagnostic and cosmeceutical companies worldwide.
With specific emphasis on peptides and complex organic molecules, Senn possesses
deep expertise of both development and production.
APC adds value to peptide production
American Peptide Company is dedicated to serving the life science community by
providing tools for peptide research. At its showcase presentation APC described
how it offers comprehensive selections of pre-manufactured catalog peptides,
custom synthesis, and GMP peptide active pharmaceutical ingredients.
The company’s California-based manufacturing facilities offer synthesis services
under non GMP (Sunnyvale) and cGMP (Vista) conditions. American Peptide’s cGMP
manufacturing is performed under strict adherence to FDA Regulations 21 CFR parts
210, 211 and ICH Guidance Q7A. Its total peptide management services support
clients in the drug development process from pre-clinical through commercial stage.
Value added services include process development, scale up production, analytical/

INFORMEX Show Daily | Thursday February 21 2013 | Anaheim Convention Center Anaheim California 5
process validation, stability studies, CMC, DMF, and regulatory support.
The company’s GMP facilities are designed for large-scale manufacturing of
pharmaceutical drug substances for clinical research. Manufacturing under cGMP
is performed under strict adherence to U.S. FDA regulations CFR 21 parts 210 and
211 and ICH guideline Q7 for Active Pharmaceutical Ingredients. SOPs (Standard
Operating Procedures) are strictly followed and meticulously documented during the
manufacturing process by a trained staff of highly qualified specialists. The company
provides complete documentation and regulatory support for your IND, NDA, and
other regulatory body submissions.
Delmar Chemicals is adding capabilities
Headquartered in LaSalle, Quebec, Canada, Delmar specializes in process
development and custom cGMP synthesis of APIs for pharma and biotech clients
that are either developing new drug candidates or that are already marketing
commercial products. In business for more than seventy years, Delmar has
established a reputation as an innovative and experienced company.
Delmar offers its clients a seamless range of integrated development solutions
for every project phase, from discovery, to proof of concept and beyond. Clients can
access Delmar’s full suite of products and services or choose from selected offerings.
The company has the expertise, the technology and the know-how to compress
timelines, maintain quality and reduce the cost of bringing drugs to market on a
global scale.
Delmar has well-equipped process R&D and analytical laboratories, a cGMP pilot
plant and commercial-scale cGMP production capabilities. In addition, Delmar offers
a full range of custom development and manufacturing services including process
development and validation.
Show-at-a-Glance
T h u r s d a y , T o d a y
7:30 am–5:30 pm Registration Open—Lobby C
7:30–10 am Networking Breakfast—Exhibition Floor Hall C & D
8–10 am Morning Conference Sessions—Marriott Anaheim
10–11am Conference Break/Exhibit Time
9 am–5 pm Exhibits Open—Halls C & D
11 am–2 pm Afternoon Conference Sessions—Marriott Anaheim
11:30 am–2 pm Networking Lunch—Exhibition Floor Hall C & D
3–4 pm Informex Speed Networking—Networking Lounge
5–6:30 pm Informex Networking Reception—Lobby D—
Sponsored by C&EN
F r i d a y , F e b r u a r y 2 2
8 am–Noon Registration Open—Lobby C
7:30–10 am Networking Breakfast—Exhibition Floor Hall C & D
9 am–Noon Exhibits Open—Halls C & D
Conference Schedule—Today
All sessions at Marriott Anaheim
8 am
Bio-based Chemicals: Going Commercial—Orange County 1
Implementing Green Chemistry Initiatives Through Open Innovation—
Orange County 2
Leaders Need Real-World Crisis Training—Elite Ballroom—Salon 2
Innovations in Formulation, Manufacturing of Emulsions—
Elite Ballroom—Salon 3
9 am
Market Regulation: How It Affects Your Business, How to Fight Back—
Orange County 1
Non cGMP Manufacturing: What I Look for in a Toller—Orange County 2
Attn Suppliers: What Keeps Me Up at Night—How Rx-360 Helps (Me Sleep
Better)—Orange County 3 and 4
Lead Optimization to First in Man Studies—Elite Ballroom—Salon 1
10 am
API Manufacturing in U.S. is Dead—Or Is it
Leaders of U.S.-based API Manufacturers Provide Their Perspectives on the
Present, Future of API Manufacturing in the U.S.—Orange County 3 and 4
11 am
Regulatory, Judicial Extremes: China vs. California—Orange County 1
Hedge Your Bets: Add Market Research to New Product Development
Process—Orange County 2
Monitoring the Biopharmaceutical Raw Material Supply—Elite Ballroom—
Salon 1
Business Valuation and the Exit Planning and Sale-of-Business Process—Elite
Ballroom—Salon 2
Noon
REACh—Preparing for May 30, 2013 and Beyond—Orange County 1
The Secret Language of Influence: Your Passport to Powerful Persuasion—
Orange County 2
Meeting the Challenge of Phase 1 Development of APIs—Elite Ballroom—
Salon 1
Leading Edge Ophthalmic Sensor Technologies for Diabetes Management—
Elite Ballroom—Salon 3
1 pm
Regulatory Challenges, Trends in Finished Dosage Manufacturing: A CMO
Perspective—Orange County 1
Market and Technology Trends in Biopharmaceutical Contract
Manufacturing—Orange County 2
Enhancing Process Economics by Combining Unit Operations—A Global
Approach to the Purification ‘Problem’—Elite Ballroom—Salon 1
Accelerating Innovation Through Strategic Outsourcing—Elite Ballroom—
Salon 2
Structure-Based Sourcing of Research Chemicals—Elite Ballroom—
Salon 3

6 INFORMEX Show Daily | Thursday February 21 2013 | Anaheim Convention Center Anaheim California
SOCMA’s Management Services
Sees Growth, Key Advocacy
Results in 2012
Members of the Bulk Pharmaceuticals Task Force met in SOCMA’s Washington, D.C., office to discuss issues important to the pharmaceutical industry,
among them the Generic Drug User Fees, which the task force was successful in advocating and seeing it become law in 2012.
SOCMA’s Association Management Services (AMS), a group of affiliated
associations and consortia that address specific issues of interest to the
chemical industry, welcomed two new members and saw continued growth
among existing members and key results from their advocacy efforts that will lead to
a safer drug supply chain.
One of the most significant accomplishments of the year came from the AMS
affiliate, the Bulk Pharmaceuticals Task Force, which finalized negotiations with the
Food and Drug Administration on a bill including Generic Drug User Fees. The FDA
Safety and Innovation Act makes it possible for the federal government to speed
approval of lifesaving medicines, reduce drug shortages, and improve the quality
and availability of drugs in the U.S.
AMS also managed four different testing consortia in 2012 in response
to the Environmental Protection Agency’s (EPA) Toxic Substances Control Act
(TSCA) Section 4 test rules for High Production Volume (HPV) chemicals. “We are
anticipating another HPV test rule in 2013 with more chemicals to be tested,” said
Dr. Tucker Helmes, managing director of AMS. “This will allow us to set up new
testing consortia, which we enjoy managing.”
AMS kicked off 2012 by welcoming the Flexible Vinyl Alliance (FVA), which
promoted the wide-ranging uses for flexible vinyl, inclusive of automotive, roofing,
flooring, and medical applications. FVA was visible in efforts to educate and inform
policy makers at both the state and federal levels on the economic and utility of
vinyl—a $20 billion U.S. industry.
SCD-iBIO, a group aiming to advance the commercialization of industrial
biotechnology, was also launched in 2012. It gives member companies an
opportunity to share best practices, have access to educational opportunities,
and take part in networking functions, held its First International Forum:
Commercializing Global Green at the Chemical Heritage Foundation (CHF) in
November. Because of the success of the first event, a second forum will be held in
November 2013 at CHF.
The Bio-Process Systems Alliance saw increases in 2012 in both numbers
and influence, as the market for disposable bio-processing platforms utilizing
plastics-technologies continued to expand. BPSA saw growth not only in the
adoption of single-use technologies in the biotechnology sectors, but also in
the adoption of single-use in traditional bio-based drug manufacture, as more
pharmaceutical companies focus on “personalized” medicines that require more
flexible, economical, and discrete manufacturing platforms. BPSA has grown from
a membership base of 38 companies when it first aligned with SOCMA in 2009 to
nearly 50 corporate members as of 2012. Visit SOCMA at Booth 2357.

INFORMEX Show Daily | Thursday February 21 2013 | Anaheim Convention Center Anaheim California 7
Members Reaping Benefits from ChemStewards Program
These days, it is imperative that
products to big multi-national chemical
chemical companies have systems,
companies.
practices and procedures in
“Our members’ customers are
place to safely and effectively operate
recognizing the value of ChemStewards
in a manner that protects and gains
and are including the program in their
the confidence of stakeholders. In just
customer audit preferences,” Jordan said.
eight years, SOCMA’s ChemStewards
“This cuts down the paperwork for our
program has gained a reputation as an
members by more than 50 percent.”
efficient and highly effective management
Some 50 SOCMA members are also
system for batch, custom, and specialty
taking advantage of a discount on insurance
manufacturers.
rates from AIG. In addition to crediting
As an industry-developed
verification costs, AIG offers participants a
environmental, health, safety, and security
number of benefits, including underwriting
program based on a three-tier system
risk management credits on policy
with key performance requirements per
premiums for the successful completion of
tier, it is the only management system
ChemStewards audits.
that is totally facility based and provides SOCMA member Dixie Chemical employees show their ChemStewards pride with arm This year, the program will focus
patches on their uniforms.
participants with adaptability to conform
greater attention on process and
while still maintaining high standards for compliance.
occupational safety, Jordan said. On May 22, ChemStewards will host the National
ChemStewards managing director Dr. J. Holland Jordan says the program is Chemical Safety Symposium in Houston, TX. National and local authorities on
helping companies bolster safety and security at their facilities while improving process and occupational safety will present the latest trends and methodologies
their bottom line. Currently, 98 percent of participants are in compliance with the used to create a safe and secure manufacturing environment. Dr. M. Sam Mannan,
program’s requirement.
director of the Mary K. O’Connor Process Safety Center at Texas A&M University,
“Our members are starting to see the payoff from a safety standpoint as well as will be the keynote speaker. An expert industry panel will discuss new techniques
a business standpoint,” said Jordan.
designed to address plant safety. Also, ChemStewards staff will address best
As specialty chemical makers, ChemStewards participants typically supply
practices in the area of process and occupations safety.

8 INFORMEX Show Daily | Thursday February 21 2013 | Anaheim Convention Center Anaheim California
LIST’s Dry Processing Technology
Reduces Plant Size, Cuts Energy Consumption
LIST USA focuses on processes that operate without the
use of solvents, or processing in the concentrated phase.
It develops and industrializes solutions for the chemical,
polymer, food, and fiber industries that are setting new
standards for modern, efficient and sustainable processing.
Its Dry Processing technology enables customers to be more
competitive by avoiding or greatly reducing the need to buy,
handle, and recycle solvents. It reduces plant size and cuts
energy consumption—shrinking capital and operating costs.
The benefits of LIST Dry Processing include: high continuous
production capacities, high degree of processing flexibilities—
changing grades, changing processing parameters; and high
efficiency operation—maximization of process yield to process
volume, energy savings. It also has ecological benefits with low
emissions and economical advantages with energy savings, low
maintenance, reduced utilities, fewer process steps and smaller
footprint. Due to its high product quality, there is no overheating,
side reactions, or contamination with degraded product.
Founded in 1966 by Heinz List, a pioneer of modern industrial processing
technology, LIST’s experience spans 45 years, including thousands of trials with a
broad range of products, and hundreds of successfully executed industrial-scale
installations.
LIST technology also provides health, safety and environmental benefits—
reducing CO2 emissions, eliminating solvents, and increasing safety through precise
thermal management.
LIST’s focus on innovation, backed by a commitment to research and
development, is evident with an expansion and modernization of their testing
facility. The expansion includes a new customer center featuring a pilot-scale, fullyautomated,
proof-of-concept system to demonstrate their two-stage continuous
process. These additions increase the process testing capabilities available to
customers, providing the ability to conduct feasibility studies, process optimization,
and scale-up evaluation, among many other things.
Visit LIST at Booth 2419.

INFORMEX Show Daily | Thursday February 21 2013 | Anaheim Convention Center Anaheim California 9
Five Minutes With…
Denis Geffroy
Vice President of Business Development
Almac
Among the challenges the industry
faces, which do you think are the
most pressing
There continues to be an ongoing
funding challenge for pharmaceutical
development. Increasing complexity of
treatments, combined with increase safety
testing, and increased price controls, creates
a major challenge in developing a profitable drug. Although the science continues
to advance, we are reaching a stage at which funding development of life-saving
treatments may become unsustainable. Creative solutions for cost control are being
implemented throughout the industry.
And what do you believe are the most creative solutions
Partnerships and collaborations are being implemented to take advantage of
strengths of various organizations. Big pharma is partnering with academics (for
example, decisions by Pfizer and Novartis among others, to move drug discovery
to Cambridge, MA to take advantage of proximity to academic excellence) and
BioTechs to increase the efficiency and reduce cost and timelines of early drug
development. Big pharma seems to have finally embraced outsourcing of significant
CMC work as a way to reduce overhead and costs. These two strategies have
provided opportunities and challenges to CMOs and CROs. Although development
pipelines have been slashed, increased outsourcing has kept the flow of CMC
development work reasonably healthy.
Although ‘one stop shop’ has carried significant negative connotations in our
industry for many years, the reality is that an efficient offering of related services
applied throughout the development cycle from a single provider has been shown
to result in significant efficiencies in both time and cost savings. The key element
is that the provider of the related services must operate a near seamless process of
delivering these services.
For example, at Almac a project can enter our business at the earliest phase
of development and benefit from chemical development and physical form
optimization (both salt and / or polymorph), analytical methods development and
biomarker or companion diagnostic development. Undertaking these early clinical
development activities can also help to reduce attrition rate – common for many
new compounds. As the compound advances into clinical trials, biocatalysis might
be employed to greatly improve the manufacturing process. The early formulation
can be quickly and efficiently developed and GMP supplies of API and Drug Product
supplied. During clinical development a radiolabeled API and DP can be provided
for ADME studies and the API process and formulation can be further refined and
scaled-up. The clinical product can be packaged, labeled and distributed worldwide
using sophisticated Drug Supply Management programs and Interactive Voice/
Web Response Systems (IXRS). Finally, the process and analytical methods will
be validated, and ultimately commercial quantities manufactured, packaged and
See 5 Minutes With…Almac page 15

10 INFORMEX Show Daily | Thursday February 21 2013 | Anaheim Convention Center Anaheim California
Organic Technologies Posts
Positive Business Outlook Based on Expanding Product Mix
Organic Technologies begins
2013 with an expanding product
mix and planned capacity
increases. The Coshocton, OHbased
fine chemicals producer
and custom manufacturer comes
to Informex with a positive
business outlook and an interest
in featuring new product growth
areas.
The privately held firm, formerly known in the industry as Wiley Organics, has
grown beyond its historical catalog business and now focuses on four key areas:
food and nutritional ingredients, fine chemicals and specialty gas components, toll
distillation and custom manufacturing.
CEO and President David B. Wiley noted that Organic Technologies’ diversity
of product mix is unusual but purposeful: “As a company with experience in both
synthetic chemistry and separations, we saw a unique opportunity to produce a
fully American sourced and manufactured omega-3 product to the highest purity
and quality standards. This was made possible by our experience in high efficiency
distillation and other purification techniques.”
In fiscal year 2012, sales revenue hit a record level and employment increased by
about 12 percent, as validation of the company’s strategy.
The functional food area has been accompanied by growth in the fine chemicals and
specialty gas components business. Jack Etheridge, VP, cited three specific developments:
“First, we have been able to step in and supply some products no longer
supplied by larger firms. Secondly, we are producing higher purity items, especially
specialty gas components. Thirdly, we are increasing our scale of production of certain
acetylenics, such as 1-butyne.”Visit Organic Technologies at Booth 1247.
PharmaCore’s In-House Analytical Chemistry
Department Supports Scale-Up Projects
PharmaCore GMP Analytical believes that it is critical to focus on supporting
projects from the ground up. PharmaCore’s team of analytical scientists interfaces
directly with scientists and process chemists from the start of each project.
From testing incoming raw materials against strictly controlled standards, through
in-process and intermediate testing support, to GMP release of final product—and
beyond, to qualification of Reference Standards and in-house support to ICH Stability
Studies—PharmaCore’s GMP analytical laboratory provides support to all projects.
With more than 100 years of combined pharmaceutical experience, the lab
now employs six full-time analytical chemists and supports all phases of in-house
contract API production from eight separate production suites. The recently
expanded 40,000 sq. ft. facility has the capability to produce 50+ Kg batch sizes
for materials in phases up to and including Phase 3.
PharmaCore’s pharmaceutical analytical services also are available on a contract
basis. In this vein, PharmaCore’s GMP analytical laboratory focuses on the API arena
and provides expertise in and support for: analytical methods development, validation
(including Residual Solvents), and transfer; cleaning validation; and consultation
Visit PharmaCore at Booth 1508.

INFORMEX Show Daily | Thursday February 21 2013 | Anaheim Convention Center Anaheim California 11
Five Minutes With…
Stewart
Tipson
Vice President
DrM
What are your major
concerns within your
market over the next two
years
Maintaining a balance
between current production
output efficiency, longterm
economic benefits and
sustainable environmental and
personnel protection. Some
new or emerging technologies
for fine chemical, biotech and
energy try to use an older
antiquated technology due to convenience. There seem to be too many low cost
fixes that do not address the problem but rather fix a symptom.
engineered solutions are simple rubber-stamped or “boiler plate” processes that do
not always have the most efficient operating and reliability characteristics of well
planned solution. Tight time constrains and budgets can limit what is available to
the client.
And what do you believe are the most creative solutions
The most creative solutions are ones that address multiple concerns in one
elegant design. Often these innovations involve planning ahead with scalable
laboratory testing, finding innovative products and solutions to meet more stringent
quality requirements or regulations.
What should be the common goals within the industry and/or
marketplace
Balancing short term goals and long term solutions. Often the tendency due
to short term cost factors is for replication of existing processes that often are not
able to adequately meet new quality or regulatory requirements over the long term.
When stringent cost analysis is undertaken it is often shown that investment in
technology today will ultimately result in a larger pay back over time. The culture
of purchasing to meet the needs of today needs to be addressed and a more
balanced approach taken to select the most relevant technology for the long-term
requirements.
Among the challenges the industry faces, which do you think are
the most pressing
Finding value-based solutions through the education of the client. Some
DrM is an international leader in providing filtration systems for solid/liquid
separation in the processing industries for the past 30 years.

2Y-Chem, Ltd, Booth 2405
Aaron Equipment Company, Booth 1424
Aarti Industries Ltd, Booth 1660
ABA Chemicals Corp, Booth 2033
ABCR GmbH & Co KG
Ace Glass, Booth 1913
ACES Pharma Inc, Booth 2043
Aceto Corporation, Booth 1201
Acoris Research Ltd, Booth 2410
ACS Green Chemistry Institute, Booth 1044
Adesis Inc, Booth 1420
Advance Research Chemicals, Inc, Booth 2532
Advanstar Communications, Booth 1053
AGC Chemicals Americas Inc, Booth 1612
Agno Pharma, Booth 2006
Air Liquide Electronics, U.S.L.P, Booth 2415
Albemarle Corporation, Booth 1430
Alfa Aesar, a Johnson Matthey Company, Booth 2310
AllessaChemie GmbH, Booth 2101
AllyChem Co, Ltd, Dalian China, Booth 1408
Almac Group ltd, Booth 1313
Alphora Research Inc, Booth 1406
Altiras Industrial Services, Booth 1529
Alzchem LLC, Booth 1909
Amano Enzyme USA Co Ltd, Booth 2430
AmbioPharm, Inc, Booth 1158
American Custom Drying Co, Booth 1301
American Peptide Company Inc, Booth 1418
AminoLogics Co Ltd, Booth 2059
Ampac Fine Chemicals, Booth 2257
Ampac Fine Chemicals, Booth MR26
AMRI, Booth 1001
Amsyn Inc, Booth 1307
Anthem Biosciences Pvt Ltd, Booth 2201
APC Ltd, The Applied Process Company, Booth 2056
Apollo Scientific, Booth 2161
Apotex Fermentation, Inc, Booth 1344
Aptuit, Booth 1619
ARRAN Chemical Co, Booth 1639
Artisan Industries Inc, Booth 1021
Ash Stevens, Inc, Booth 1552
Ash Stevens, Inc, Booth MR7
A-Star Chemical Co, Ltd, Booth 1219a
Astatech, Inc, Booth 1011
Asymchem Laboratories (Tianjin) Co, Ltd, Booth 2138
Asymchem Laboratories (Tianjin) Co, Ltd, Booth MR25
Aurora Filters, Booth 1150
Austin Chemical Company, Inc, Booth 1225
BASF Corporation, Booth 1439
BASF Corporation, Booth MR3
BCN Peptides SA, Booth 1029
Beijing Century RICHAP Chemistry Co, Ltd,
Booth 1359
Beijing Laviana Pharmatech Co, Ltd, Booth 2124
Beijing Odyssey Chemicals Co, Ltd, Booth 2009
Beijing Tianqing Chemicals.Co,Ltd, Booth 2015
Benzo Chem Industries Pvt. Ltd, Booth 2423C
Bharavi Laboratories, Booth 921H
Biazzi SA, Booth 1758
BioReliance Corporation, Booth 921L
Biovectra Inc, Booth 2156
Boehringer Ingelheim Pharma GmbH & CoKG,
Booth 2351
Boron Molecular USA, Booth 1421
Boron Specialties LLC, Booth 1608
Borregaard Synthesis, Booth 1038
Boulder Scientific Company, Booth 1309
Browz, LLC, Booth 1620
Buchiglas USA Corp, Booth 2301
Buckman Laboratories, Booth 1912
C&EN/ACS Publications, Booth 2447
CABB AG, Booth 2350
CAC Chemical Co Ltd, Booth 1533
CalaChem Ltd, Booth 1119
Calaire Chimie S.A.S., Booth 1501
Cambrex Corporation, Booth 1539
Cambrex Corporation, Booth MR2
Cambridge Major Laboratories, Booth 2225
CAP Intelligence, Booth 2260
CARBOGEN AMCIS AG, Booth 2529
CARBOGEN AMCIS AG, Booth MR36
Carbosynth Ltd, Booth 2423E
Cardolite Corporation, Booth 2221
Carus Corporation, Booth 2423D
CAS, Booth 1009
Catalent Pharma Solutions, Booth 2414
CatSci, Booth 921C
CCPIT Sub-Council of Chemical Industry, Booth 1521
CCR Containers, Booth 1355
Cedarburg Pharmaceuticals Inc, Booth 1207
Cedarburg Pharmaceuticals Inc, Booth MR5
CellMark Chemicals, Booth 1258
Centauri Technologies LP, Booth 1658
Central Glass International, Inc, Booth 2157
Changzhou EST Chemical Co Ltd, Booth 1459
Changzhou Sunlight Fine Chemical Co,Ltd, Booth 2011
Charkit Chemical Corporation, Booth 1649
CHEM Group, Inc, Booth 1746
Chemada / ICL-IP, Booth 1561
ChemCon GmbH, Booth 1501
ChemDesign Products, Inc, Booth 1603
ChemFuture PharmaTech (Jiangsu) Ltd, Booth 2144
Chemglass Life Sciences, Booth 2409
Chemical Week, Booth 1946
Chemicals Incorporated, Booth 1957
CHEMIK Co, Ltd, Booth 1402
Chemindustry.com, Inc, Booth 2028
Chemlex Pharmaceuticals LLC, Booth 2445
ChemNexus Inc, Booth 2230
Chemoswed, Booth 2201
Chempacific Corporation, Booth 1907
Chemspec API Corp., Booth 2450
Chemtura Corp., Booth 1548
Chevron Phillips, Booth 1712
Chifeng Yingfa Pharmaceutical Co, Ltd, Booth 1128
China Chamber of Commerce of Med. & Heal,
Booth 1147a
China National Pharmaceutical Foreign Co,
Booth 2446
Chiral Quest Inc, Booth 1522
Chiral Technologies, Inc, Booth 2432
Chiral Technologies, Inc, Booth MR27
CiNet, Booth 1626
CiVentiChem, LLC, Booth 2153
Clean Harbors Environmental Services, Inc, Booth 1354
Colonial Metals Inc, Booth 2047
CompareNetworks Inc, Booth 1048
Contract Chemicals Ltd, Booth 1447
Corden Pharma International GmbH, Booth 1801
Corning SAS, Booth 933
CorsiTech, Booth 2331
COSMOSS VU Ltd, Booth 2110
CRI, Booth 1644
Crystallics BV, Booth 1252
CU Chemie Uetikon GmbH, Booth 1545
Custom Granular, Inc, Booth 1407
Cymer, LLC, Booth 1744
Dae Hwa Pharmaceutical Co, Ltd, Booth 1047
Daewoong Bio Inc, Booth 1144
Dalchem, Booth 2444
Dalian Joinking BioChemical Tech Co, Ltd,
Booth 1249
Dalian Richfortune Chemicals Co, Ltd, Booth 1206
DanChem Technologies, Inc, Booth 2012
Danyang Wanlong Chemical Co,Ltd, Booth 1214
DavosPharma, Booth 2201
DCAT (Drug, Chemical & Associated Tech,
Booth 1947
Deepwater Chemicals Inc, Booth 1461
DELMAR Chemicals INC, Booth 2049
Digital Specialty Chemicals, Booth 1160
Dishman USA, Booth 2531
Dixie Chemical Company, Inc, Booth 2231
Dottikon Exclusive Synthesis AG (USA), Booth 2119
Dr. M Inc, Booth 1758
Dr. Reddy’s Laboratories Ltd, Booth 1901
Drug Development & Delivery, Booth 1010
DSL Chemicals (Shanghai) Co, Ltd, Booth 1546
DSM Pharmaceutical Products Inc, Booth 1401
DyStar L.P., Booth 1926
Eastar Chemical Corp., Booth 2133
eChinaChem, Inc, Booth 1948
Enzyme Works Inc , Booth 2423B
Enzymicals AG, Booth 1014
Equinox Chemicals, LLC, Booth 1748
Esteve Quimica, S.A., Booth 2238
Euticals, Inc, Booth 1633
Euticals, Inc, Booth MR6
Evonik Degussa Corp, Booth 1239
Evonik Degussa Corp, Booth MR8
Exova, Booth 1119
F.I.S.–Fabbrica Italiana Sintetici SpA, Booth 2049
F.I.S.–Fabbrica Italiana Sintetici SpA, Booth MR28
Far Chemical, Inc, Booth 1139
Fareva, Booth 2046
Farmabios SpA, Booth 1253
Farmhispania S.A., Booth 1259
Federal Equipment, Booth 2030
Fermion Oy, Booth 2231
Ferro Pfanstiehl Laboratories, Booth 2232
Flamma Spa, Booth 1802
FMC Lithium, Booth 1438
Fontarome Chemical Inc, Booth 1351
Frau Pharma srl, Booth 921O
Fuji Chemical Industry Co, Ltd, Booth 1654
Fuji Silysia Chemical Ltd, Booth 2347
FutureFuel Chemical Co, Booth 1653
Fuzhou Sanhe Pharmachem Co, Ltd, Booth 1618
Gabriel Performance Products, Booth 1423
Galbraith Laboratories Inc, Booth 1002
Gelest Inc, Booth 1318
GFS Chemicals Inc, Booth 1930
GL Filtration Ltd, Booth 1150
Grace/Synthetech, Booth 2039
Gran Formosa Inc, Booth 921P
Guangzhou Runhua Food Additive Co, Ltd, Booth 2244
GVK Biosciences Pvt. Ltd, Booth 1509
Halocarbon Products Corp, Booth 1155
Hamari Chemicals Ltd, Booth 2401
Haviland Products Co, Booth 2061
Hebei Chengxin Co, Ltd, Booth 2128
Helsinn Advanced Synthesis SA, Booth 1809
Helsinn Advanced Synthesis SA, Booth MR9
HERBRAND PharmaChemicals GmbH, Booth 1014
Heritage Environmental Services, Booth 2424
Hodogaya Chemical (USA) Inc, Booth 1261
Hongye Chemical Co, Ltd, Booth 2108
Hopax Tawain Chemical Mfg, Booth 1015
Hovione, LLC, Booth 2330
Huaian MDC Pharmaceutical Co, Ltd, Booth 1120
Hubei Greenhome Fine Chemical Co, Ltd, Booth 2248
Hydrite Chemical Co, Booth 1610
ICO Polymers North America, Booth 1621
InChem Corp, Booth 1652
InCon Processing, LLC, Booth 1613
Ind Swift Laboratories Ltd, Booth 1960
Indoco Remedies Ltd, Booth 2253
Indofine Chemical Company Inc, Booth 2206
INFA Group SpA, Booth 1225
Informex Global Pharma Sourcing, Booth 1709
Informex Sales Booth, Booth 1709
Informex Specialty Chemical Forum, Booth 1709
Ingenza Ltd, Booth 1119
Insight High Technology Co, Ltd, JiangSu, Booth 2122
Interchem Corporation, Booth 1501
International Process Plants (IPP), Booth 1908
Iofina Chemical Inc, Booth 2333
IRIX Pharmaceuticals Inc, Booth 1813
IRIX Pharmaceuticals Inc, Booth MR10
IRIX Pharmaceuticals Inc, Booth MR11
ISOCHEM, Booth 1738
Italian Trade Commission, Booth 1705
J&W Pharmlab, Booth 1027
Jan Ramakers Fine Chemicals Consulting, Booth 1119
Jiangsu Huifeng Agrochemical Co, Ltd, Booth 2001
Jiangsu Lanfeng Biochemical Co, Ltd, Booth 2104
Jiangsu Medicines & Health Prod. I&E Gro, Booth 2005
Jiangxi Renming Pharmaceutical Co, Ltd, Booth 2023
Jiangxi Time Chemical Co, Ltd, Booth 1147a
Jinhong Fine Chemicals, Booth 1361
Johann Haltermann Ltd, Booth 2307
Johnson Matthey, Booth 2310
Johnson Matthey, Booth 2311
Johnson Matthey Catalysis and Chiral, Booth 2311
J-Star Research, Inc, Booth 1343
J-Star Research, Inc, Booth MR12
Julabo USA, Inc, Booth 1559
Kalexsyn, Inc, Booth 1552
Kingchem Inc, Booth 1450
Kingfirst Chemical (Nanjing) Co, Ltd, Booth 2246
KMCO Inc, Booth 1929
Kodak Specialty Chemicals, Booth 1742
Lacamas Laboratories Inc, Booth 2325
Lacamas Laboratories Inc, Booth MR13
Laohekou Jinghong Chemical Co, Ltd, Booth 1628
LAUDA-Brinkmann, LP, Booth 1607
Laurus Pvt. Ltd, Booth 1924
Laviana Corp, Booth MR23
LCI Corporation, Booth 2247
Lianhe Chemical Technology Co, Ltd, Booth 1413
Lishui Nanming Chemical Co, Ltd, Booth 2112
LIST USA Inc, Booth 2419
LOBA Chemie PVT Ltd, Booth 2024
Lonza, Booth 1052
Lonza, Booth MR15
Lonza, Booth MR16
Louisiana Chemical Equipment Co, Booth 1345
Louston International Inc, Booth 1700
Lundbeck Pharmaceuticals Italy SpA, Booth 1800
Manchester Tank & Equipment Company, Booth 1153
McGean,Inc, Booth 1511
Metallix,Inc, Booth 1448
MFG Chemical, Inc, Booth 2438
Micromacinazione SA, Booth 1225
Micron Technologies, Booth 2418
Minakem, LLC, Booth 2320
Mitrychem, Booth 1919
Mitsubishi International PolymerTrade, Booth 2500
Mitsui & Co (USA), Inc, Booth 2321
Mitsui & Co (USA), Inc, Booth MR29
Molekula Group, LLC, Booth 2423G
Monomer-Polymer & Dajac Labs, Booth 2045
Morre-tec Industries, Inc, Booth 2107
MP Biomedicals LLC, Booth 1953
MRIGlobal, Booth 1314
MSU Bioeconomy Institute, Booth 2142
Muller Group, Booth 1961
Na Fluorochem(H.K) International Co, Li, Booth 1521
Nagase & Co, Ltd, Booth 2411
Nanjing Pharmatechs, Co, Ltd, Booth 2208
Nantong Kaixin Pharma Chemical Co, Ltd, Booth 1622
Nation Ford Chemical Co, Booth 1518
Navin Fluorine International Ltd, Booth 1409
Neuland Laboratories, Booth 1159
Newreka Green & Synth Technologies Pvt.,
Booth 2423F
Niels Clauson-Kaas A/S, Booth 2201
Norac Pharma, Booth 1039
Noramco, Inc, Booth 1143
Norquay Technology Inc, Booth 1032
Northeast Pharmaceutical Group Co, Ltd, Booth 2100
Nova Molecular Technologies, Inc, Booth 1442
Novasep Inc, Booth 1939
Oakwood Products Inc, Booth 1109
Olon Spa, Booth 1703
OmegaChem, Booth 1023
ONYX Scientific, Booth 1910
Optima Chemical Group, LLC, Booth 1639
Organic Technologies, Booth 1247
Ortec Inc, Booth 1238
Panjin Xingfu Chemical Industrial Co, L, Booth 1553
Parchem Fine & Specialty Chemicals, Booth 2240
Patheon, Booth 1107
Paul O Abbe, Booth 1424
PCAS, Booth 1601
PCAS, Booth MR14
PCI Synthesis, Booth 1059
Pennakem, Booth 2318
PepTech Corp, Booth 2057
Perry Videx LLC, Booth 2327
Pharmachem, Booth 2251
Pharmacore, Inc, Booth 1303
Pharmax, Booth 2224
PharmaZell, Inc, Booth 1253
PHT International Inc, Booth 1419
Pierre Fabre Medicaments, Booth 1353
PIERS, Booth 1950
PII Pharmaceutics International Inc, Booth 2426
Piramal Healthcare, Booth 2439
POLAQUIMIA S.A. DE C.V., Booth 1312
Polypeptide Laboratories, Booth 2127
Polysciences Inc, Booth 1242
Pope Scientific Inc, Booth 1254
Porton Fine Chemicals Ltd, Booth 1453
Powdersize, Inc, Booth 1215
Pressure Chemical Co, Booth 1458
Procos USA (CBC Group), Booth 2226
PYOSA S.A. DE C.V., Booth 1526
Qi-Chem Co Ltd, Booth 1630
Qingdao Union Fine Chemical Co Ltd, Booth 1219b
Quanzhou Sanwei Chemical Industry Co, L,
Booth 2250
R.S.A. Corporation, Booth 1213
Regis Technologies Inc, Booth 1339
Rhodes Technologies, Booth 1706
Ricerca Biosciences, Booth 2060
Rieke Metals, Inc, Booth 2348
RightAnswer.com, Inc, Booth 1624
Robatel Inc, Booth 1352
Robinson Brothers, Booth 2219
Robinson Pharma, Booth 921G
Rockwood Lithium, Booth 1659
Rodman Publishing, Booth 2146
Rohner Inc, Booth 2215
Rondaxe Pharma LLC, Booth 1648
Ropella, Booth 1346
Rx-360, Booth 2152
SABIC Innovative Plastics, Booth 1449
Sai Life Sciences Ltd, Booth 2109
Sai Life Sciences Ltd, Booth MR24
Saltigo GmbH, Booth 2131
Saltigo GmbH, Booth MR30
SantoLubes Mftg., dba Blackman Uhler,
Booth 1920
SAS Institute Inc, JMP Division, Booth 2443
Scottish Development International, Booth 1119
Scynexis Inc, Booth 2339
Senn, Booth 1058
Senn, Booth MR18
Shaanxi Dasheng Pharmaceutical Tech Co, Booth 1110
Shamrock Technologies, Inc, Booth 2423P
Shandong Hexing Pharmacy Co, Ltd, Booth 1212
Shandong Jiuheng Int’l Trade Co, Ltd, Booth 2252
Shanghai AQBioPharma Co, Ltd, Booth 1141
Shanghai Chemspec Corp., Booth 2450
Shanghai Record Pharmaceuticals Co, Ltd, Booth 2029
Shanghai Shyndec(Modern) Pharmaceutical , Booth 1108
Shanghai Sinofluoro Chemicals Co, Ltd, Booth 1631
Shanghai T&W Pharmaceutical Co, Ltd,
Booth 1609
Shenyang Photosensitive Chemical Research,
Booth 2126
Shenzhen Nexconn Pharmatechs Ltd, Booth 921K
Shijiazhuang No 4 Pharmaceutical Co, Ltd,
Booth 1114
Shouguang Fukang Pharmaceutical Co, Ltd,
Booth 1147b
Siegfried (USA), Inc, Booth 1101
Silar Laboratories, Booth 2045
Siltech Corporation, Booth 1349
Sinobright Pharmaceutical Company Ltd, Booth 2403
Sinochem Lantian Co, Ltd, Booth 1523
SK Life Science, Inc, Booth 1506
SOCMA, Booth 2357
SOCMA Member Lounge, Booth 2457
Solid Form Solutions Ltd, Booth 1925
Solvay Fluorides LLC, Booth 2239
Solvias Inc, Booth 2211
Spectrum Chemical Mfg, Corp, Booth 1944
SSI Chusei, Inc, Booth 2346
SST Corporation, Booth 2231
Strem Chemicals Inc, Booth 1319
Sumitomo Chemical Europe S.A. / N.V., Booth 2413
Suven Life Sciences USA, Booth 2125
Suzhou Everfortune Imp.&Exp. Co, Ltd, Booth 1246b
Suzhou Highfine Biotech Co, Ltd, Booth 1208
Synasia Inc, Booth 1400
Syngene International, Booth 2050
SynQuest Laboratories, Inc, Booth 2159
SYNTHON Chemicals GmbH & Co KG, Booth 1922
T10 Chemicals, Booth 921D
Takasago International Corp, Booth 2148
Takasago International Corp, Booth MR33
TCG Lifesciences, Booth 2147
TCI America, Booth 1940
Tekno Scienze SRL, Booth 2412
The Chemical Company, Booth 2400
Thomson Reuters, Booth 1000
Tianjin Jingye Fine Chemicals Co, Ltd, Booth 2019
TM Chemicals LP, Booth 2256
Topharman Shanghai Co, Ltd, Booth 2145
Tosoh USA Inc, Booth 1625
TrustChem Co, Ltd, Booth 2139
Ubichem Pharma Services, Booth 2433
UBM Live, Booth 1709
Umicore AG & Co KG, Booth 1131
United Biochemicals, Booth 1954
Upscale Microwave Inc, Booth 1525
US EPA Green Chemistry Program, Booth 2423i
Valsynthese S.A, Booth 1501
VanDeMark Chemical, Inc, Booth 1321
Varsal Inc, Booth 1224
Veolia Environmental Services, Booth 2008
Vertellus Specialties Inc, Booth 1113
Virto/Elcan Industries, Booth 2453
Waterstone Pharmaceuticals Inc, Booth 1558
Weatherford, Booth 1358
Weihai NewEra Chemical Co, Ltd, Booth 2258
Western States Machine Corp., Booth 2345
WeylChem Corporation, Booth 1801
WIL Research, Booth 1513
Wilmington Pharma Tech Co, LLC, Booth 1702
Wockhardt Ltd, Booth 1125
WuXi AppTec Inc, Booth 2113
Xi’an Ruilian Modem Electronic Chemicals,
Booth 1006
Xiangfan Goto Chemical Co, Ltd, Booth 1126
Yangzhou Chemical Co ltd, Booth 1527
Yixing Qiancheng Bio-Engineering Co, Ltd, Booth 1122
Yizheng City East Chemical Co, Ltd, Booth 1112
Zach System S.P.A., Booth 1701
Zepol, Booth 1030
Zhangjiagang Feihang Industry Co, Ltd, Booth 2027
Zhejiang Apeloa Kangyu Pharmaceutical Co,
Booth 1915
Zhejiang Charioteer Pharmaceutical Co, L, Booth 2132
Zhejiang Jianfeng Haizhou Pharmaceutical,
Booth 2319
Zhejiang Medicines & Health Products I/E, Booth 2005
Zhejiang Taizhou Qingquan Medical & Chem,
Booth 2013
Zhejiang Tianyu Pharmaceutical Co, Ltd, Booth 2118
Zhejiang Tongfeng Pharma & Chem. Co, Ltd,
Booth 2025
Zhejiang Yongning Pharmaceutical Co, Ltd ,
Booth 1246a
Zhongdan Group, Booth 1549
Zhong dan Group, Booth MR4

14 INFORMEX Show Daily | Thursday February 21 2013 | Anaheim Convention Center Anaheim California
Nova Molecular Adds
New Distillation Capacity
Nova Molecular Technologies has completed its latest capital expansion project
adding new distillation and reaction capacity at the Pasadena, TX, manufacturing
site. This new capacity will support Nova Molecular’s growth in its current specialty
chemical product portfolio and custom manufacturing business.
In addition to manufacturing capacity onsite, Nova has added strategic
products to its portfolio: 2-Methyltetrahydrofuran, Acetonitrile, and an
amine based line of Epoxy Curing Agents. These products fit well with the
Tetrahydrofuran, Tetrahydrofurfuryl Alcohol, and amine-based products
currently being produced.
To support Nova’s belief in having sound technology behind both
its proprietary and custom products, upgrades to the onsite research
and development lab have been implemented with a quality control lab
expansion planned in 2013. The capabilities of both labs are designed
around being able to support the hydrogenation, pressure reactions, and
fractional distillation unit operations that have become Nova’s specialty. To
complement the labs, the R&D and technical staff have experience and focus
on the implementation of safe, cost effective, and efficient processes.
Nova strives to be an extension to the customer’s supply chain. The
company’s goal starts with the sales and business development team
understanding the needs/goals of each project and product requirements.
This is followed by Nova’s technical staff evaluating and integrating the
process into its facility.
Visit Nova Molecular at Booth 1442.
Ricerca Biosciences Enhances
Chemical Development and
Manufacturing Capabilities
Ricerca Biosciences, a U.S.-
based CRO, is committed to
maintaining its reputation as a
supplier of Active Pharmaceutical
Ingredients (APIs) and Specialty
Chemicals. This includes
production of material to
support market development
and clinical activities in addition
to commercial supply. The
company’s extensive process chemistry, analytical chemistry, and engineering
expertise provides a synergy that excels at first-time scale-ups and subsequent
development of safe, reliable, robust and cost-effective manufacturing processes.
Meeting the needs of the client has been the foundation of Ricerca’s business
philosophy and is second only to its commitment to safety and regulatory
compliance.
Ricerca continues to strategically increase its chemical development and
manufacturing capabilities to meet the needs of its clients through improved
efficiency and cost-effective delivery of services. Recent upgrades to its plant facility
include the addition of 200- and 400-liter glass-lined steel reaction systems capable
of low-temperature operation. The additional reactor capacity increases the nominal
reactor volume of its cGMP plant facility to 17,000 liters.
Visit Ricerca at Booth 2060.

INFORMEX Show Daily | Thursday February 21 2013 | Anaheim Convention Center Anaheim California 15
Umicore Builds a New Facility
for its Precious Metals Chemistry Business Unit
In response to a series of new business
opportunities identified by the U.S. Marketing
and Business Development team,
Umicore’s Precious Metals Chemistry
(PMC) business unit will significantly
expand its manufacturing capabilities by
constructing a new production facility at
the Umicore campus in Tulsa, OK.
This facility will be based on the
latest technologies and is designed to
manufacture Umicore’s entire portfolio
of precious metal-based catalysts and
chemicals including advanced products,
such as ruthenium metathesis catalysts
and palladium cross-coupling catalysts.
“The ability to operate on a global
basis is one of our primary drivers.
Building the Tulsa production facility
will allow PMC to supply our customers
in North America with today’s most
advanced organometallic catalysts
and chemicals conveniently and costeffectively,”
said Matthias Grehl, VP,
Precious Metals Chemistry.
Production is scheduled to begin in
the fourth quarter of 2013 and will be
fully operational in early 2014.
When completed, the facility
will include a range of reactor sizes
allowing PMC to provide customers
with uninterrupted supply of catalysts
from early development through
commercial-scale production. It will
be constructed using flexible-design
infrastructure and equipment so that
both current and future organometallic
catalysts developed by Umicore’s R&D
group can be readily produced. The
facility also has additional square
footage designated for a second-phase
plant expansion and sits on a 53-acre
campus with significant room for added
manufacturing capacity.
Umicore PMC’s current operation in
South Plainfield, NJ, will be phased-out
and activities will be integrated into the
new facility.
Visit Umicore at Booth 1131.
Cambrex
Inks Facility
Expansion
Cambrex has entered into an
agreement to supply an active
pharmaceutical ingredient for a
customer’s Phase 3 program during
2013 and 2014. Under this nonexclusive
supply arrangement, Cambrex
will manufacture and deliver Phase
3 and pre-launch quantities of this
product candidate.
Cambrex currently is expanding its
Charles City, IA, facility to increase its
multi-purpose cGMP production capabilities
related to this opportunity. The
expansion started in August 2012 with
anticipated completion in late February.
Cambrex is a life sciences company
that provides products, services
and technologies to accelerate the
development and commercialization of
small molecule therapeutics.
Visit Cambrex at Booth 1539.
From Almac page 9
distributed. All of these services are
provided from a single Almac site with
integrated technical teams managing
the process from earliest development
through launch.
Almac provides a comprehensive range
of services extending from research
through pharmaceutical and clinical
development to commercialisation of
product.

16 INFORMEX Show Daily | Thursday February 21 2013 | Anaheim Convention Center Anaheim California
J-Star Expands
Its Research
Horizons
J-STAR Research, a contract research and small scale manufacturing
CRO based in South Plainfield, NJ, has significantly strengthened its
capabilities in the areas of cGMP manufacturing, analytical support,
quality assurance, and chemistry personnel over the past year as a way to
continuously provide clients a “Center of Excellence” in the field of small
molecule process research and cGMP manufacturing.
Areas that have been expanded include hiring of additional analytical
chemists to support analytical method development and method
qualification/validation supporting cGMP manufacturing, and bringing
additional key quality assurance personnel with decades of industrial
experience to assist in ensuring high quality assurance standards.
The company has also brought on board chemistry personnel from
some of the leading process research groups at major pharmaceutical
companies in the New Jersey area. In addition, the company has acquired
extensive equipment to broaden the technical capabilities of the company
including an RC1 and a 20L high pressure hydrogenator. Visit J-STAR at
Booth 1523.
Oakwood Responds
to Clients’ Needs
Oakwood Chemical is a supplier of chemicals for research and development
for more than 20 years. Its new facility on a 42-acre campus in Estill, SC.
houses a seasoned staff of manufacturing chemists. Oakwood responds
rapidly to the client’s needs for synthesis of non-GMP intermediates, from
grams to multiple kilos. Since Oakwood maintains an inventory of reagents,
solvents and intermediates, time and costs of projects can be reduced.
Oakwood’s laboratories handle difficult materials and reactions. The
high-pressure area routinely uses Sulfur Tetrafluoride and Hydrogen Fluoride
to Fluorinate and catalyzed Hydrogen for reductions. The labs can utilize
high hazard materials, such as Hydrogen Sulfide, Thionyl Chloride, N-Butyl
Lithium, Chlorine, Bromine, Phosphorous Oxychloride and others.
Whether clients are looking for a blocking reagent, such as Boc
Anhydride, or a transportation sensitive compound, such as Trichloroacetyl
Chloride, Oakwood carries an inventory in the U.S., as well at Hadfield,
U.K. The company’s products are backed by its own in-house Quality
Control department, using GC, GC-Mass, Chiral analysis, LC, NMR, and wet
methods. Oakwood Chemical understands its clients’ needs as it is owned
and managed by chemists.
Visit Oakwood Chemical at Booth 1109.

INFORMEX Show Daily | Thursday February 21 2013 | Anaheim Convention Center Anaheim California 17
Five Minutes With…
Edward S. Price
President
PCI Synthesis
What are your major concerns
within your market over the next
two years
I’ve got two concerns about trends
affecting the industry. The first is whether
funding for small, emerging companies will
continue. For a while small biotechs got
funding from both the public markets and
venture capital. When the funding from the public markets dried up, the small
biotechs revamped their business model, became more virtual and developed
a greater dependence on VCs for funding. The greater shift to reliance on VC
funding has had a significant impact on the size, scope and approach that emerging
biotechs now take to develop their products. We’re also seeing that VC funding is
slowing as well. So where does that leave small biotechs Right now the primary
exit strategy for VC-backed biotechs is to get acquired by big pharma.
The problem, and my second concern, is that big pharma continues to
consolidate. Pfizer and Wyeth merged; Merck and Schering-Plough merged;
AstraZeneca bought Ardea Biosciences and Bristol-Myers Squibb and AstraZeneca
jointly bought Amylin Pharmaceuticals.
Today most VC-based biotechs’ exit strategy is to be acquired by big pharma
player. With big pharma focused on merging with former competitors, there
are fewer and fewer big pharma firms remaining. This thus limits the number of
potential acquirers that will drive down prices, and, in turn, could drive down
funding. The net result: loss of creativity and dwindling access to funding which will
make value creation even more challenging.
Among the challenges facing the industry, which one do you think
is the most pressing—and why
I think big pharma consolidation is the most pressing challenge facing the
industry. The question is: Will there be enough opportunities for promising biotechs
to sell their technologies Fewer big pharma companies mean fewer companies
looking to acquire small companies. Aside from the business implications, this
means that we may be missing out on the kinds of research that small biotechs can
undertake—research that could lead to breakthroughs but that, at the outset, look
unlikely to generate the kind of blockbuster returns that drive big pharma.
What innovation (not your own company’s) do you believe has
addressed a problem with a creative solution
There is a great deal of work going on with continuous manufacturing. It is very
innovative and inspiring because it seeks to dramatically change pharmaceutical
manufacturing for both drug substance and drug product and has the potential
to greatly improve efficiencies. But at the end of the day, a significant part of the
challenge with continuous manufacturing won’t be the technological issues but
regulatory issues such as how the process will be managed and how to deal with
See 5 Minutes With…PCI Synthesis page 19

18 INFORMEX Show Daily | Thursday February 21 2013 | Anaheim Convention Center Anaheim California
DFI Pharma to Represent CU in North America Region
CU Chemie
Uetikon, a
custom research
and manufacturer
of Active
Pharmaceutical
Ingredients (NCEs
and Generic
Drugs), has
appointed DFI
Pharma, as
representative of
Chemie Uetikon’s
business in North America. The change became effective last summer.
DFI Pharma will represent CU for specialty fine chemicals, pharmaceutical
intermediates, contract research—custom synthesis with supporting development;
and custom manufacturing of new chemical entities.
For more than 14 years, Faghani served Chemie Uetikon as a director of North
America region. He will now continue his co-operation with CU as an independent
representative and authorized distributor in the same region.
Registered in April 2012, David Faghani Inc. is a legal entity, a New Jersey corporation
with a principal place of business at 65 Richmond Drive, Skillman, NJ 08558.
CU’s new representative office is a milestone in the company’s strategy to affirm
its commitment to fine chemicals and pharmaceutical markets and to provide better
service and support to all CU’s customers, agents and distributors.
DFI Pharma will offer customers options to choose how they wish to be served.
The main focus will be to provide direct commercial support to CU’s customers
in collaboration with CU’s agents and distributors and to develop new business
opportunities in the America market.
DFI Pharma offers many services to exclusive principal
David Faghani Incorporated (DFI Pharma), a privately held multi-national sourcing and
supplier of pharmaceutical ingredients, specializes in sales, marketing, distribution, and
commercial development (market segments & research analysis) for high quality products
and services offered by its exclusive principal.
Their products and services include: specialty fine chemicals; GMP
pharmaceutical intermediates; advanced intermediates; contract research—
custom synthesis with supporting development, analytics, quality and regulatory
documentations; APIs (NCEs) manufactured under full cGMP—contract
development and manufacturing of new chemical entities and niche generic
representing an increasing part of our business; new developmental of generic APIs
manufactured under full cGMP; and out-licensing of new generic APIs through a
network of pharmaceutical drug manufacturers having a strong compliance system
in place, as well as, meeting all regulatory requirements.
With 30 years of experience serving the specialty chemical and pharmaceutical
markets, from early stage development to commercial, DFI Pharma has gained
an understanding of its sectors while creating strong and long-term business
partnerships. Intellectual properties rights will remain a fundamental factor in the
development of NCEs or new generic drugs.
DFI Pharma actively promotes and defends the right of its clients and principal
partners with regard to patent and regulatory issues.
Visit Chemie Uetikon and DFI Pharma at Booth 1545.

INFORMEX Show Daily | Thursday February 21 2013 | Anaheim Convention Center Anaheim California 19
From PCI Synthesis page 17
it from a quality assurance and quality
control perspective. As in other areas
of technology—like driverless cars—the
regulations will be lagging behind the
technology.
What should be the common
goals within the industry and/
or marketplace
There are two areas at least where I
see the industry should work together.
The first is to help attract and train
employees to the industry. We should
all embrace as a common goal the
need to get behind training people in
the skills they need to be employed.
We need more qualified technical folks
to do the work that we all need to
get done. This shortage of qualified
employees is going to get worse over
the next few years.
The second area is dealing with
regulations. Perhaps if, as an industry,
we worked to raise standards, we could
achieve the same goals without incurring
the costs of meeting new regulations.
On the one hand, we’re trying
to drive down the cost of health care
while we’re increasing the demands
and costs of manufacturing. Those are
incompatible goals. As an industry,
we’re going to have to figure a way to
balance out the demands and the costs.
development. That’s going to be a
significant issue impacting all of us.
What are two strategies—either
personal or professional—you
feel important to initiate this
yearCost-cutting Additional
capital expenditure Additional
marketing investments Team
building More emphasis on
social media
Due to increasing regulations,
we’re seeing that our projects are
getting to be more complicated from
a technical, GMP, and regulatory
paperwork perspective. There’s more
for us to manage. We’re going to have
to develop more resources to manage
projects, and the details of around
those projects. So that’s going be to a
strategic focus for us. The other focus
is to prepare for a number of product
launches that we’re expecting over the
next 18 months. We’re working on
getting the organization ready for when
those products launch. Because of the
increasing levels of new regulations and
our own new product launches, we’re
expecting to have to hire more people.
We will need to boost the training of
our current employees to be able to
execute and meet the needs of our
customers.
PCI Synthesis is a pharmaceutical
manufacturer of new chemical entities
(NCEs), generic active pharmaceutical
ingredients (APIs), and other specialty
chemical products.
What is one relevant question
(and your answer) that you
believe no one is addressing
adequately
Right now, aside from the funding
issue, the big question is this: Where
are the next generation of employees
going to come from It’s harder today
than ever to find qualified people.
Three quarters of the prospective
technical employees we see are
foreign born. We see a lot of talented
candidates from India and China. But
because quality of life, including salaries
and job opportunities, are improving
in those countries, fewer candidates
are seeking jobs in this country. The
skills gap is only going to widen as
similarly smart kids in the U.S. seem
to prefer working for Google or Apple
or an app company, which is seen as
“cooler” than working in biotech or
pharmaceutical manufacturing and

20 INFORMEX Show Daily | Thursday February 21 2013 | Anaheim Convention Center Anaheim California
A t D e a d l i n e
Chemicals Incorporated Posts Extensive Experience
For more than 30 years, Chemicals Incorporated has provided
the specialty chemicals industry with custom manufacturing
and chemical intermediates at the lowest possible cost. With
two Texas facilities—Baytown and Bay City—and rail capabilities,
CI can manage supply chain requirements efficiently. CI’s
extensive experience with a broad spectrum of chemical reactions,
significant R & D lab expertise, pilot plant, and scale up
capabilities can facilitate fast commercialization and market introduction of projects. CI is
ISO 9000 registered and has advanced processing equipment and highly qualified staff
to create value meeting your expectations. For details on chemicals toll manufacturing,
private brand capabilities, or cost/performance advantage, contact: www.chemicalsinc.
com/(281) 576 5000—Rich Miskowski, Chuck Castley, or Pal Arjunan. Visit Chemicals
Incorporated at Booth 1957.
Biazzi Features In-house Test Center
Biazzi is a leading global provider of engineering, technologies, services, and hardware
systems for the manufacture of explosives, for the nitration of aromatics, and for catalytic
gas-liquid reactions. Scale-up and process and optimization for gas-liquid reactions are
performed in its in-house test center and build the basis for the design of the industrial
plant, with associated process guarantees. Industrial plants are provided with a size of up
to 50m3 reactor volume. Pressure and temperature limits are 200bar and 300°C. Biazzi’s
scope of supply ranges from the delivery of the basic engineering and the key-equipment
up to the delivery of complete modular plants (SKIDs) for all areas of the chemical, pharmaceutical,
plastic industry, and for parts of food industry. Visit Biazzi at Booth 1758.
Pope Scientific Showcases Wide Range of Services
Pope Scientific offers distillation toll processing services and equipment,
including wiped film molecular (short-path), evaporation, and novel hybrid
fractional column distillation technologies for heat sensitive materials with close
boiling points. The company provides lab, pilot plant, and production scale
capabilities. Toll services for kosher and GMP requirements are available. Pope
Scientific has batch and continuous type turnkey fractional column distillation
sytems and components in stainless steel and Hastelloy, as well as Nutsche
filter-dryers, benchtop size, pilot, and production sizes. There are pressure
vessels and turnkey process vessel systems, reactors, fermenters, mixing,
blending, dispensing, and other processes, custom designed and built to suit the
application, as well as pressurizable sanitary mixers. Visit Pope Scientific
at Booth 1254.
DrM On-going Filtration Systems Leader
DrM, Dr. Müller AG, and its U.S. subsidiary DrM Inc. have been and continue
to be one of the international leaders in providing filtration systems for solid/
liquid separation in the processing industries for the last 30 years. DrM has more
than 2800 of its main products—the FUNDABAC and CONTIBAC Filters—in
operation worldwide and approximately 130 new systems are put in place every
year. Applications and uses are widespread in various industries, such as chemicals,
polymers, oil and gas, steel, pharmaceuticals, food and food additives, and
electronics. DrM has added the FUNDAMIX to its family of products. It is a universal
device for mixing liquids in open or closed vessels, under vacuum or pressure, even
under sterile conditions. Visit DrM at Booth 1758.

INFORMEX Show Daily | Thursday February 21 2013 | Anaheim Convention Center Anaheim California 21
Federal Equipment’s
Experience Translates
into Buying Power
Federal Equipment offers an array of
services, including the liquidation and
auction of process lines and manufacturing
facilities, equipment appraisals, among
others. It provides extensive buying and
selling experience, purchasing power, and
global marketing reach, supplies API and
specialty chemical machinery.
Experience in various specialized
markets enables it to provide clients with
asset disposition solutions, regardless of
the size, location, or complexity of the
project. With its value-added strategies
that advance clients’ investment recovery
goals, its customized solutions maximize
profitability.
A strategic relationship with Pfizer
provides Federal Equipment with stock
that includes the used process and
packaging equipment. Visit Federal
Equipment at Booth 2030.
Advertisers
Index
AMPAC Fine Chemicals, Booth 2257,
www.ampacfinechemicals.com ...........2
Ash Stevens, Inc., Booth 1552,
www.ashstevens.com .............. Cover
BioVectra Inc., Booth 2156,
www.biovectra.com ....................8
Cambridge Major Laboratories, Inc.,
Booth 2225, www.c-mlabs.com ..........19
C&EN, Booth 2447, cen.acs.org .......17, 18, 20
Chemtura Corp., Booth1548,
www.chemtura.com ...................8
DFI Pharma, Booth 1545,
www.dfipharma.com ...................9
Evonik, Booth 1238,
www.evonik.com/pharma ..............24
Fabbrica Italiana Sintetici SpA,
Booth 2049, fisvi.com .................11
Federal Equipment Co., Booth 2030, www.
fedequip.com .......................17
Helsinn Advanced Synthesis S.A., Booth 1809,
www.helsinn.com ....................10
J-Star, Booth 1343,
www.jstar-research.com ...............14
LIST USA Inc., Booth 2419, www.list.us .......21
Nova Molecular Technologies, Inc.,
Booth 1442, www.novamolecular.com ......9
Oakwood Products, Inc., Booth 1109,
www.oakwoodchemical.com ............23
Organic Technologies, Booth 1247,
www.organictech.com .................14
PCI Synthesis.com, Booth 1059,
www.pcisynthesis.com .................16
PharmaCore, Inc., Booth 1303,
www.pharmacore.com ................15
Ricerca Biosciences, Booth 2060,
www.ricerca.com .....................21
Siegfried USA, Inc., Booth 1101,
www.siegfried.ch .....................16
Umicore AG & Co. KG, Booth 1131,
www.umicore.com ....................7
Zach Stystem S.P.A., Booth1701,
www.zachsystem.com .................18

22 INFORMEX Show Daily | Thursday February 21 2013 | Anaheim Convention Center Anaheim California
History is in the making at C&EN this year, as the publication celebrates its
90th anniversary with a variety of landmark initiatives, including a special
Sept. 9 issue profiling significant chemistry milestones. Additionally, its vast
archives are spotlighted online each week, where a pictorial blog features
provoking chemistry-related contests.

INFORMEX Show Daily | Thursday February 21 2013 | Anaheim Convention Center Anaheim California 23
In a session Wednesday, Lalit Baregama, CEO and president of Syngeny, briefed the audience
about the latest applications of specialty chemicals to drive technical innovation.
From API Sourcing page 1
tion technology skills for data and customer management, and political stability.
Due to regulatory challenges and escalating costs, Speace suggested that
companies wanting to do business with India consider the environmental, health,
and safety records of suppliers there. Additionally, they should find out whether
the drug is licensed by the Indian government, whether the company has ISO
certifications and regulatory inspections. “When asking how committed your
supplier is, you should determine operating and regulatory history, investments in
facilities and talent, presence in your market, and customer support programs in
place,” he said.
From Green Chemistry page 1
In the pharmaceutical supply chain, outsourcing is driven by cost, flexibility
requirements, and increasing capabilities of contract manufacturing organizations.
Companies must design sustainability into products and processes from inception
and have early, frequent assessment, Constable said, adding “Finding the right
balance is challenging.”
Green chemistry spurs innovation when companies think about improving the
environment while obtaining equal or better performance from green processes and
remaining economically viable. The principles of green chemistry are maximizing
resource efficiency, eliminating or minimizing hazards, designing systems holistically,
and using life cycle thinking, according to Constable.
Last year’s National Science Foundation’s Sustainable Chemistry Workshop concluded
that systems level thinking is required, more fundamental research should be
use-inspired, and green is not synonymous with sustainable. Furthermore, efficiency
is necessary but not sufficient, and sustainability research and education should be
multi-disciplinary and collaborative. “We have to develop a different set of skills,”
Constable said, adding that the process can be streamlined by finding the right metrics
“that are simple, meaningful, essential, and based on systems already in place.”
The business of green chemistry has to emphasize how new or replacement markets
will affect revenues, how greater efficiency and automation will reduce costs, how
business and government processes will impact risks, how intangibles will affect the
company’s image, and how new strategies will affect value and quality.
ACS roundtables are showing companies how to collaborate non-competitively,
address technical challenges, develop decision-making tools, and add resources to
the supply chain.
“Chemical companies have to understand that the risks are real, early
design makes green chemistry workable, and resources are available,”
Constable concluded.
Thomas Speace, president and CEO of Neuland Laboratories
India’s high degree of government control lends itself to bureaucracy and
corruption, Speace said. “Patience is more than a virtue,” he added. “Invest the
time to build relationships.”
China is even bigger and more diversified, with unique cultures and languages
in different provinces, according to Hui-Yin (Harry) Li, president of Wilmington
PharmaTech Co. Most API production takes place along the Pacific coast where
water for manufacturing is vital.
Li cautioned that sometimes doing business depends on how American companies
can support the capabilities of API suppliers in China to overcome deficiencies.
“You need to know the boss and how he operates the place,” he said. “You have
to understand the company’s relationship with the local government, the suppliers’
resources, and whether they can invest in facilities and sustain growth.”
API producers in China evolved from small town-owned chemical shops, cityowned
local pharmaceutical companies, trading companies, new ventures managed
by “returnees,” shops run by academics, and a combination. Some companies fail
quickly, so companies doing business with them have to be vigilant regarding recent
performance, current assets and capabilities, as well as the backgrounds of the
people and organizations running them.